



## Next Generation Histone Deacetylase (HDAC) Inhibitors

Guest Editors:

**Prof. Dr. Thomas Kurz**

Heinrich-Heine-Universität  
Düsseldorf, Institute for  
Pharmaceutical and Medicinal  
Chemistry, Universitätsstraße 1,  
40225 Düsseldorf, Germany

**Prof. Dr. Finn K. Hansen**

Institute of Pharmacy, Leipzig  
University, Brüderstraße 34,  
04103 Leipzig, Germany

Deadline for manuscript  
submissions:

**closed (31 January 2019)**

### Message from the Guest Editors

Dear Colleagues,

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for the treatment of cancer. Thus far, four histone deacetylase inhibitors (HDACi) have been approved by the FDA to combat certain types of lymphoma or multiple myeloma. Furthermore, there is growing evidence that HDACi have therapeutic potential in several diseases beyond cancer, such as inflammation, HIV, and parasitic and neurodegenerative diseases. First-generation inhibitors are non-selective HDACi that target multiple isoforms which might lead to serious side effect. In the field of cancer, it is currently under debate whether class- or isoform-selective HDACi can provide improved risk-benefit profiles compared to first-generation pan-inhibitors. In the field of non-oncology diseases, it is evident that the use of pan-HDACi is limited due to their side effects.

The aim of this Special Issue is to highlight recent efforts in the design, synthesis, and pharmacological evaluation of next-generation histone deacetylase inhibitors. We welcome original articles and short communications as well as review articles.

Prof. Dr. Thomas Kurz  
Prof. Dr. Finn K. Hansen  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical  
Biology and Phytochemistry,  
University of Münster,  
Corrensstrasse 48, D-48149  
Münster, Germany

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

## Contact Us

*Molecules* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/molecules](http://mdpi.com/journal/molecules)  
[molecules@mdpi.com](mailto:molecules@mdpi.com)  
[X@Molecules\\_MDPI](https://twitter.com/X@Molecules_MDPI)